)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jazz Pharmaceuticals
Jazz Pharmaceuticals (JAZZ) investor relations material
Jazz Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary2 Nov, 2026
Executive summary
Record Q3 revenue of $1,243.0M, up 10% YoY; Oncology grew 35% and Xywav 12%, supporting raised FY26 revenue guidance of $4.775B-$4.85B.
Ziihera’s first-line HER2-positive GEA launch and the Actio acquisition of ABS-1230 added commercial and pipeline growth drivers; zanidatamab peak sales potential is $3B-$5B.
Financial highlights
Q3 revenue was $1,243.0M versus $1,126.1M in Q3 2025; nine-month revenue rose 15% to $3,520.2M.
Q3 GAAP net loss was $483.4M, or $7.48 per diluted share; adjusted net loss was $250.8M, or $3.88 per diluted share.
Q3 operating loss was $413.4M; nine-month operating income was $171.4M versus a $684.8M loss in 2025.
Nine-month net income was $2.5M, including a $122.8M PRV-sale gain; prior-year results included litigation costs and a $206M deferred-tax benefit.
Outlook and guidance
FY26 revenue guidance rose to $4.775B-$4.85B from $4.6B-$4.75B; rare sleep revenue guidance is $2.125B-$2.175B.
Adjusted gross margin guidance is 90.5%-91.5%; adjusted SG&A is $1.33B-$1.37B, adjusted R&D $725M-$775M, and adjusted tax rate 19.5%-21.5%.
Xywav is expected to grow low double digits to low teens; combined rare oncology and epilepsy revenue is expected to grow at double digits.
Milestones include initial ABS-1230 data in 4Q26, ACTION results in 1H27, Epidiolex capsule PDUFA on April 16, 2027, and EmpowHER-303 data in late 2027 or early 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jazz Pharmaceuticals
- Oncology growth, zanidatamab expansion, and robust financials drive a strong diversified outlook.JAZZ
Morgan Stanley 24th Annual Global Healthcare Conference - Zanidatamab and EPIDIOLEX anchor a robust pipeline targeting oncology and epilepsy growth.JAZZDeutsche Bank 2026 Healthcare Summit
- Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook.JAZZCitigroup’s Biopharma Back to School Summit 2026
- Strong commercial execution and pipeline innovation drive robust growth and future potential.JAZZWells Fargo 21st Annual Healthcare Conference
- FDA approved Ziihera regimens for first-line HER2+ GEA, setting a new survival benchmark.JAZZFDA announcement
- Q2 2026 revenue up 16% YoY to $1.21B; 2026 guidance raised on strong portfolio growth.JAZZQ2 2026
- Shareholders will vote on director nominees and five proposals at the July 2026 AGM.JAZZProxy filing
- Strong neuroscience growth and robust pipeline progress offset oncology headwinds, supporting 2024 outlook.JAZZBank of America 2025 Healthcare Conference
- Q1 2025 revenue steady at $898M; Chimerix closed; 2025 outlook affirmed despite headwinds.JAZZQ1 2025
Next Jazz Pharmaceuticals earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
Jazz Pharmaceuticals
Next Jazz Pharmaceuticals earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing treatments for neurological disorders, sleep medicine, and oncology. The company’s portfolio includes products designed to address rare and complex conditions, particularly in the areas of sleep disorders, epilepsy, and cancer. Jazz Pharmaceuticals engages in research, development, and global distribution of its therapies, working to advance treatment options for patients with unmet medical needs. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.